Messenger RNA (mRNA) News and Research

RSS

Silence completes siRNA research work with AstraZeneca, MedImmune

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces the successful completion of its research work under the Research Collaboration and Delivery Collaboration with its partner AstraZeneca and its biologics arm, MedImmune.

7 Jan 2012

KCC Director recognized for distinguished contributions to cancer care

Richard Pestell, M.D., Ph.D., FACP, Director of the Kimmel Cancer Center at Jefferson (KCC), has been named a 2011 Fellow of the American Association for the Advancement of Science.

16 Dec 2011

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.

14 Dec 2011

People with myotonic muscular dystrophy more likely to develop cancer

People who have the most common type of adult muscular dystrophy also have a higher risk of getting cancer, according to a paper published today in the Journal of the American Medical Association.

14 Dec 2011

Research: lncRNA affects apoptosis and plays a role in RBC development

A long non-coding RNA (lncRNA) regulates programmed cell death during one of the final stages of red blood cell differentiation, according to Whitehead Institute researchers. This is the first time a lncRNA has been found to play a role in red blood cell development and the first time a lncRNA has been shown to affect programmed cell death.

8 Dec 2011

Researchers sequence entire transcriptome of mouse neural retina

The population of Eric Morrow's seminar "Neurogenetics and Disease" comprises mainly undergraduates who were skipping down the halls of their elementary schools when the first drafts of human genome sequences were published. When Morrow, assistant professor of biology, recently asked the class how to find the mutation behind a disease, a hand shot up in the back of the class to signal the answer: "Sequence the patient's genome."

8 Dec 2011

Ribosomes spontaneously change their form during protein production

Ribosomes, the construction sites for proteins, are far more complex than previously assumed. During the production of proteins they constantly and spontaneously change their form. This performance of eukaryotic ribosomes has now been demonstrated for the first time by scientists at Charité - Universitätsmedizin Berlin, the Max-Planck-Institut für Molekulare Genetik in Berlin, and Cornell University in New York, with the aid of special electron microscopic and biophysical methods.

24 Nov 2011

Cisplatin anti-cancer drug binds pervasively to RNA

An anti-cancer drug used extensively in chemotherapy binds pervasively to RNA -- up to 20-fold more than it does to DNA, a surprise finding that suggests new targeting approaches might be useful, according to University of Oregon researchers.

21 Nov 2011

New method for counting molecules

Researchers at the Swedish medical university Karolinska Institutet have developed a new method for counting molecules.

21 Nov 2011

New genetic approach to treat fibrodysplasia ossificans progressiva

Scientists at Penn's Perelman School of Medicine Center for Research in FOP and Related Disorders have developed a new genetic approach to specifically block the damaged copy of the gene for a rare bone disease, while leaving the normal copy untouched.

9 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Ground-breaking study into causes of high blood pressure

A researcher from the University of Leicester's Department of Cardiovascular Sciences has been involved in a ground-breaking study into the causes of high blood pressure.

9 Nov 2011

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

9 Nov 2011

Gen-Probe receives FDA approval for APTIMA HPV assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has approved its APTIMA HPV assay, an amplified nucleic acid test that detects high-risk strains of human papillomavirus (HPV) that are associated with cervical cancer and precancerous lesions.

31 Oct 2011

Two proteins bind together to ignite and sustain malignant brain tumors

Two previously unassociated proteins known to be overly active in a variety of cancers bind together to ignite and sustain malignant brain tumors, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports this week in the journal Cancer Cell.

22 Oct 2011

Scientists uncover vast new gene regulatory network linked with cancer

Researchers at Columbia University Medical Center (CUMC) and two other institutions have uncovered a vast new gene regulatory network in mammalian cells that could explain genetic variability in cancer and other diseases.

15 Oct 2011

Scientisits uncover evidence of powerful new cancer genetic networks

In findings with major implications for the genetics of cancer and human health, researchers at Beth Israel Deaconess Medical Center (BIDMC) and two other science teams in New York City and Rome have uncovered evidence of powerful new genetic networks and showed how it may work to drive cancer and normal development.

14 Oct 2011

Idera announces new data on novel gene-silencing oligonucleotide technology

Idera Pharmaceuticals, Inc. today presented new data on its novel gene-silencing oligonucleotide (GSO) technology at the Cell Symposium on Regulatory RNAs in Chicago, IL.

12 Oct 2011

New siRNA treatment reduces damaging inflammation in animals models of several disorders

Massachusetts General Hospital (MGH) researchers - along with collaborators from Massachusetts Institute of Technology (MIT) and Alnylam Pharmaceuticals - have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions.

10 Oct 2011

New technique could give a preview of which eggs are likely to make the most viable embryos

Given the stakes of in vitro fertilization, prospective parents and their doctors need the best information they can get about the eggs they will extract, attempt to fertilize, and implant. New research at Brown University and Women & Infants Hospital of Rhode Island has found a way to see which genes each egg cell is expressing without harming it.

7 Oct 2011